Evidence map›Paper›PMID 37238609›Full record

ArticleBiomolecules2023

Epitope-Specific Anti-SerpinB3 Antibodies for SerpinB3 Recognition and Biological Activity Inhibition.

Alessandra Biasiolo, Michele Sandre, Stefania Ferro, Santina Quarta, Mariagrazia Ruvoletto, Gianmarco Villano, Cristian Turato, Maria Guido, Oriano Marin, Patrizia Pontisso

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alessandra BiasioloDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Michele SandreDepartment of Biomedical Sciences, University of Padova, Via Colombo 3, 35131 Padova, Italy.ORCID 0000-0002-3013-6908
Stefania FerroDepartment of Biomedical Sciences, University of Padova, Via Colombo 3, 35131 Padova, Italy.
Santina QuartaDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.ORCID 0000-0002-9348-1485
Mariagrazia RuvolettoDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Gianmarco VillanoDepartment of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Cristian TuratoDepartment of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.ORCID 0000-0001-7086-0792
Maria GuidoDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Oriano MarinDepartment of Biomedical Sciences, University of Padova, Via Colombo 3, 35131 Padova, Italy.
Patrizia PontissoDepartment of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
University of Padua · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SerpinB3 is a serine protease inhibitor that plays a relevant role in disease progression and cancer by increasing fibrosis, cell proliferation, and invasion, besides conferring resistance to apoptosis. The mechanisms underlying these biological activities are not yet fully understood. The aim of this study was to generate antibodies directed against different SerpinB3 epitopes to better investigate their biological role. Five exposed epitopes were identified using the software DNASTAR Lasergene and the corresponding synthetic peptides were used for NZW rabbit immunization. Anti-P#2 and anti-P#4 antibodies were able to recognize both SerpinB3 and SerpinB4 by ELISA. Anti-P#5 antibody, produced against the reactive site loop of SerpinB3, showed the greatest specific reactivity for human SerpinB3. This antibody was able to recognize SerpinB3 at nuclear level, while anti-P#3 antibody recognized SerpinB3 only at cytoplasmic level, both by immunofluorescence and by immunohistochemistry. The biological activity of each antibody preparation was assessed in HepG2 cells overexpressing SerpinB3 and anti-P#5 antibody reduced proliferation by 12% cell and cell invasion by 75%, while trivial results were obtained with the other antibody preparations. These findings indicate that the reactive site loop of SerpinB3 is essential for the invasiveness features induced by this serpin and it could become a novel druggable target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsDisease ProgressionEnzyme-Linked Immunosorbent AssayHep G2 CellsHumansRabbitsimmunogenic epitopesserine protease inhibitory activitySerpinB3SerpinB4

Identifiers

PMID37238609
PMCPMC10216589
OpenAlexW4366991567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.